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The Heart of Glass-Cerebral Cavernous Malformation (Heg-CCM) pathway is essential for normal
cardiovascular development in zebraﬁsh and mouse. In zebraﬁsh, the Heg-CCM pathway mutants santa
(ccm1/san), valentine (ccm2/vtn), and heart of glass (heg) exhibit severely dilated hearts and inﬂow tracts
and a complete absence of blood circulation. We identiﬁed a novel gene based on its sequence identity
with ccm2, which we have named ccm2-like (ccm2l), and characterized its role in cardiovascular
development. Disruption of ccm2l by morpholino injection causes dilation of the atrium and inﬂow
tract and compromised blood circulation. Morpholino co-injection experiments identify ccm2l as an
enhancer of the characteristic Heg-CCM dilated heart phenotype, and we ﬁnd that ccm2 overexpression
can partially rescue ccm2l morphant defects. Finally, we show that Ccm2l binds Ccm1 and perform
deletion and mutational analyses to deﬁne the regions of Ccm1 that mediate its binding to Ccm2l and
its previously established interactors Ccm2 and Heg. These genetic and biochemical data argue that
ccm2l is a necessary component of the Heg-CCM pathway.
& 2013 Elsevier Inc. All rights reserved.Introduction
The zebraﬁsh is tremendously useful for the identiﬁcation and
characterization of genes that control heart development, as both
heart morphology and its functional output, blood circulation, are
easily visible in the transparent, externally developing embryo.
The embryonic zebraﬁsh heart contains two chambers, one
atrium and one ventricle, and each consists of two tissues:
endocardium, which is a specialized endothelium that lines the
inside of the heart, and the muscular myocardium that generates
the contractile force. Embryos homozygous mutant for three
different genes—ccm1 (santa/san), ccm2 (valentine/vtn), and heart
of glass (heg)—exhibit the same striking phenotype: the heart and
inﬂow tract are massively dilated, and although the heart beats,
there is no blood circulation (Mably et al., 2006; Mably et al.,
2003). They die around 5 days post fertilization (dpf), which is a
general feature of mutants that cannot form a functional cardio-
vascular system. ccm1, ccm2, and heg are conserved across
vertebrate species; their murine homologs Ccm1, Ccm2, and
Heg1, respectively, are essential for normal cardiovascularll rights reserved.
0 Longwood Avenue, Enders
731 0787.
. Rosen),
(L.Y. Ye),development in mouse (Boulday et al., 2009; Kleaveland et al.,
2009; Whitehead et al., 2009; Whitehead et al., 2004).
ccm1, ccm2, and heg interact genetically as components of a
signaling system known as the Heart of Glass-Cerebral Cavernous
Malformation (Heg-CCM) pathway. In zebraﬁsh, slight knock-
down of any of the three genes can drastically enhance heart
phenotypes in embryos sensitized by a subphenotypic dose of
morpholino against either of the other two (Mably et al., 2006).
Similarly, the phenotype conferred by deletion of Heg1 in
mouse is enhanced in animals haploinsufﬁcient for Ccm2
(Kleaveland et al., 2009). CCM1, CCM2 and HEG1 proteins also
interact biochemically. Co-immunoprecipitation, FRET, and yeast
2-hybrid experiments have demonstrated physical interactions
between human CCM1 and CCM2 (Zawistowski et al., 2005;
Zhang et al., 2007). CCM1contains three NPXY/F motifs, ankyrin
repeats, and a band 4.1, ezrin, radixin, moesin (FERM) domain.
CCM2 contains a phosphotyrosine binding (PTB) domain that is
required for the CCM1–CCM2 interaction (Zawistowski et al.,
2005). The NPXY/F motifs in CCM1 are targets of the PTB domain
in CCM2, and disrupting these motifs singly or pairwise causes
decreased CCM1–CCM2 binding (Zawistowski et al., 2005; Zhang
et al., 2007). HEG1 is a single pass transmembrane protein whose
intracellular domain binds the CCM1–CCM2 complex (Kleaveland
et al., 2009).
There is strong evidence that the Heg-CCM pathway functions
in the endothelium. Conditional mouse knockouts where Ccm2 is
selectively deleted from the developing endothelium phenocopy
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activity is required in the endothelium (Boulday et al., 2009;
Whitehead et al., 2009). In situ hybridization experiments in
zebraﬁsh embryos detect heg in the endocardium but not the
myocardium, consistent with a model in which Heg-CCM signal-
ing in the heart’s endothelium regulates heart morphology
(Mably et al., 2003). Adult mice heterozygous for Ccm2 exhibit
vascular leakiness (Stockton et al., 2010) and hypersensitivity to
the hemorrhagic effects of VEGF injection (Whitehead et al.,
2009), and this phenotype is recapitulated in endothelial cell
culture where loss of CCM1 or CCM2 causes increased monolayer
permeability (Crose et al., 2009; Glading et al., 2007; Stockton
et al., 2010; Whitehead et al., 2009). These studies demonstrate
that the Heg-CCM pathway is conserved across vertebrates and
required in the endothelium for normal cardiovascular develop-
ment and adult physiology.
The Heg-CCM pathway is so-named because mutations in the
human CCM1 and CCM2 genes cause vascular anomalies called
cerebral cavernous malformations (CCMs) (Denier et al., 2004;
Laberge-le Couteulx et al., 1999; Liquori et al., 2003; Sahoo et al.,
1999). CCMs, which affect approximately 0.5% of the population,
are malformations of the brain vasculature characterized by an
expanded endothelial vessel that can result in headache, seizure,
hemorrhage and death (Revencu and Vikkula, 2006). CCMs can
arise either spontaneously or as an autosomal dominant heredi-
tary condition. In addition to CCM1 and CCM2, a third gene, CCM3,
also causes CCMs when mutated (Bergametti et al., 2005). In
overexpression studies, CCM3 protein can bind CCM2 (Hilder et
al., 2007; Li et al., 2010; Voss et al., 2007; Zheng et al., 2010), and
knockdown of its two zebraﬁsh homologs, ccm3a and ccm3b,
affects heart development, though there are conﬂicting character-
izations of this phenotype (Voss et al., 2009; Yoruk et al., 2012;
Zheng et al., 2010). Since loss-of-function of ccm1 and ccm2
causes severe endothelial vessel dilation in both the embryonic
zebraﬁsh heart and the adult human brain, the zebraﬁsh heart
may provide insights into the genetic and cellular interactions
that underlie human CCM disease.
Unlike other signaling pathways that have been studied
extensively, the Heg-CCM pathway was discovered only recently
and as a result remains incompletely understood. We employed a
straightforward bioinformatic approach to identify a novel gene
with sequence identity to ccm2, which we have named ccm2-like
(ccm2l). Using morpholinos to knock down ccm2l in zebraﬁsh
embryos, we found that loss of ccm2l causes dilation of the atrium
and inﬂow tract and a lack of blood circulation. Slight reduction of
ccm2l causes a dilated heart phenotype in embryos sensitized by a
sub-phenotypic dose of ccm1 morpholino, deﬁning ccm2l as an
enhancer of the Heg-CCM pathway. Injection of ccm2 mRNA can
partially rescue cardiovascular defects in ccm2l morphants, sug-
gesting that ccm2 and ccm2l have overlapping in vivo functions.
We demonstrate that Ccm2l protein binds Ccm1; moreover, we
interrogate this interaction further to deﬁne the Ccm1 NPXY/F
motif requirements for this interaction, which are different from
those for Ccm1–Ccm2 binding. Finally, we suggest that the
human homolog of ccm2l, C20ORF160, may have relevance to
human CCM disease.Materials and methods
Zebraﬁsh
All zebraﬁsh husbandry procedures were performed in accor-
dance with protocols approved by the Institutional Animal Care
and Use Committee at Boston Children’s Hospital. Zebraﬁsh
embryos were raised in egg water at 28.5 1C. Tubingen and(ﬂi1:EGFP)y1 (Lawson and Weinstein, 2002) zebraﬁsh lines were
used. For some experiments, embryos were incubated in 0.003%
1-phenyl 2-thiourea (PTU) after 1 day of development to inhibit
pigment formation.
Expression analysis
In situ hybridization was performed as previously described
(Mably et al., 2006; Mably et al., 2003). RT-PCR was performed
either using the OneStep RT-PCR kit (Qiagen) on total RNA
extracted from embryos by Trizol (Life Technologies) or by
performing reverse transcription on total RNA using the Quanti-
Tect Reverse Transcription Kit (Qiagen) followed by PCR. The
following primers were used:
ccm2: 50-CGTCTATACCGAGTCCACCA-30, 50- AGGAGTCTTCACTGTA-
GATTGAG-30. ccm2l: 50- AGGTCAAGTTCCTGGGACAC-30, 50- CAGACAG-
ACTGAGAATACAGTCC-30. ccm1: 50- CATAATAGGGAAGCGTGTTGTG-30,
50- GGAGGAGAAATGAGCACTGG-30. gapdh: 50- GGCAAACTGGTCATT-
GATGG-3, 50-CTTAATGTGAGCAGAAGCCT-30.
cmlc2: 50-GGAGAGAAGCTCAATGGCACA-30, 50-GTCATTAGCAG-
CCTCTTGAACTCA-30.
insulin: 50-GTG GAT CTC ATC TGG TCG ATG C-30, 50–AGG AGG
AAG GAA ACC CAG AAG G-30 (as in (Burns and MacRae, 2006)).
b-actin: 50-GCTGTTTTCCCCTCCATTGTT-30, 50-TCCCATGCCAAC-
CATCACT-30.
Hearts were puriﬁed from whole embryos as previously
described (Burns and MacRae, 2006).
Embryo microinjection
Morpholinos, designed by Gene Tools, LLC, were diluted in
water to make stock solutions and further diluted in water
containing a ﬁnal concentration of 0.1% phenol red for injections.
Embryos were injected in the yolk with 1–2 nL of diluted
morpholino no later than the 2-cell stage using a PLI-100 pico-
injector (Harvard Instruments) and subsequently raised at 28.5 1C.
The following morpholinos were used:
ccm1: 50-GCTTTATTTCACCTCACCTCATAGG-30
ccm2l:MO e4i4: 50-ACATTTCACTCTTACTAACCAGTTT-30,
MO e2i2: 50-TCAGACTAGACCTTGACCTCCTTCT-30.
ccm2: 50-GAAGCTGAGTAATACCTTAACTTCC-30.
Standard control MO: 50-CCTCTTACCTCAGTTACAATTTATA-30.
In experiments to characterize the ccm2l knockdown pheno-
type, we injected 1.0 pMol MO e4i4 or 0.3 pMol MO e2i2. For
enhancer experiments, pairwise combinations of morpholino
were injected as single solutions. For experiments with either
MO e4i4 or MO e2i2, each 1 nL injection volume contained
0.01 pMol ccm1 MOþ0.05 pMol ccm2l MO, 0.01 pMol ccm1
MOþ0.05 pMol standard control MO, or 0.01 pMol standard
control MOþ0.05 pMol ccm2l MO. The experimenter was blinded
to these solutions prior to injection. For rescue experiments,
embryos were ﬁrst injected with morpholino (0.3 pMol MO e2i2
or 1.0 pMol MO e4i4), randomly sorted into three groups, and
then injected a second time with 0.1 ng ccm2wt mRNA or 0.1 ng
ccm2m201 mRNA. (The third group was left singly injected.) The
experimenter was blinded to these treatments prior to assaying
phenotypes at 52 hpf.
The morpholinos against ccm1 and ccm2 were previously
validated (Mably et al., 2006). To validate morpholinos against
ccm2l, total RNA was isolated from embryos injected with
morpholino and uninjected control embryos using Trizol reagent
(Life Technologies) as per the manufacturer’s instructions. The
RNA was then subjected to reverse transcription PCR (RT-PCR)
using the OneStep RT-PCR kit (Qiagen) with exonic primers
ﬂanking the exon-intron boundary targeted by the morpholino.
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on an agarose gel. The following PCR primers were used:
ccm2l: 50-TGGACTATGATCCCAAGCGAACCA-30, 50-GGGTTCAGGG-
AACAGGACACCCA-30.
ccm2: 50- ATGGAGGAGGATGTAAAGAA-30, 50- TCAGGTATCCAG-
GAACTGAGG -30.
The ccm2l MO e2i2 and uninjected PCR products were sub-
cloned into the PCRII-TOPO vector (Life Technologies) and
sequenced.
mRNA preparation
Capped RNA was transcribed in vitro from linearized pCS2-
ccm2, pCS2-ccm2m201, and pXT7-ccm2le2i2 templates using the
mMessage mMachine SP6 or T7 Ultra kits (Life Technologies) and
puriﬁed using the MEGAclear kit (Life Technologies). As the last
step of the puriﬁcation, RNA was eluted in water and subse-
quently diluted in water and phenol red (ﬁnal concentration of
0.1%) prior to injection.
Microscopy
Live zebraﬁsh embryos were mounted on a microscope slide in
4% methyl cellulose without a coverslip. Imaging was accom-
plished on a Nikon Eclipse 90i microscope equipped with a
CoolSNAP HQ2 camera (Photometrics) using NIS-Elements soft-
ware. Images were subsequently processed in Adobe Photoshop.
Cloning and plasmid generation
ccm2l was cloned from cDNA reverse transcribed from total
RNA isolated from 2 dpf zebraﬁsh embryos. The following forward
and reverse primers were designed with an EcoRI site and a XhoI
site, respectively, to allow for subcloning of the PCR product into
pCMV-HA (Clontech):
50-GATCGAATTCAAATGGACTATGATCCCAAGCG-30,
50-GATCCTCGAGTCACAAGTAATAATCCTCCTC-30.
pCMV-HA-ccm2 was generated by performing PCR on a pCS2-
ccm2 template (previously described (Mably et al., 2006)) with
primers containing EcoRI and XhoI restriction sites followed by
digestion and ligation into pCMV-HA. The following primers were
used:
50-GATCGAATTCAAATGGAGGAGGATGTAAAGAAAG-30,
50-GATCCTCGAGTCAAGATGGCACGCCGTCTTG-30.
Zebraﬁsh heg was cloned into pCMV-Myc (Clontech) by per-
forming PCR on a heg cDNA template (Open Biosystems clone
903796) using primers containing EcoRI and XhoI cut sites,
followed by digestion and ligation. The following primers
were used:
50-GATCGAATTCAAATGATGGAAACGTGCGCTCG-30,
50-GATCCTCGAGTCAAAAGTAGTCTCTTCGGCGTG-30.
Ccm1 deletion constructs were generated by performing PCR
on full-length ccm1 cDNA template with primers containing EcoRI
or XhoI restriction sites and subcloning PCR fragments into
pCMV-tag2b (Stratagene). The following PCR primers were used:
pCMVtag2b-ccm1:
50-GATCGAATTCATGATGGGAAACCAAGAGCTAG-30,
50-GATCCTCGAGTTACCCATACGCATATTTATC-30.
pCMVtag2b-ccm1DNPXY/F:
50-GGAATTCAAATGGCAGCACAGCATGACC-30,
50-ACCGCTCGAGTTACCCATACGCATAT -30.
pCMVtag2b-ccm1DNPXY/F-ANK:
50-GGAATTCTGGGAGGAAACCGTGAATCTC-30,
50-ACCGCTCGAGTTACCCATACGCATAT -30.
pCMVtag2b-ccm1DFERM:
50-GGAATTCATGGGAAACCAAGAGCTAGAG-30,50-ACCGCTCGAGGAGATTCACGGTTTCCTC-30.
FLAG-ccm1ty219c and FLAG-ccm1m775 were generated using
the same primers and vector as pCMVtag2b-ccm1, but with PCR
templates containing the appropriate ccm1 alleles.
Point mutations were inserted in pCMVtag2b-ccm1 using the
QuikChange II Site-Directed Mutagenesis Kit (Stratagene). The
following primers were used:
Y193A:
50-GTGAGTAACCCGGCGGCCGCAGTGGAGAAGCA-3,
50-TGCTTCTCCACTGCGGCCGCCGGGTTACTCAC-30.
Y231A:
50-CATCCAGAACCCGCTGGCCGGCTCAGATCTGCAG-30,
50-CTGCAGATCTGAGCCGGCCAGCGGGTTCTGGATG-30.
Y249A,F250A:
50-ACAGAGTGGACAAAGTCATCATCAACCCTGCCGCTGGCTTGG-
GAGCTCC-3,
50-GGAGCTCCCAAGCCAGCGGCAGGGTTGATGATGACTTTGTC-
CACTCTGT-30.
pXT7-ccm2le2i2 was generated by shuttling the MO e2i2
induced RT-PCR product (i.e. the upper band containing an
intronic insertion) from PCRII-TOPO to pXT7.
Cell culture and immunoblotting
For co-immunoprecipitation studies, 293T cells grown in
Dulbecco’s Modiﬁed Eagle’s Media (DMEM) containing 10% fetal
bovine serum were transfected at 80–100% conﬂuence in 6-cm
dishes with Lipofectamine-2000 (Life Technologies) essentially as
per the manufacturer’s instructions. Two days after transfection,
cells were washed brieﬂy in PBS and lysed on ice in immunopre-
cipitation buffer containing 30 mM Tris, 150 mM NaCl, 1% Triton
X100, and Complete protease inhibitor (Roche). Lysates were
agitated for ten minutes at 4 1C and then centrifuged for ten
minutes at 14,000 rpm at 4 1C. Small samples of each supernatant
were removed and stored at 201 to be later run on gels as
inputs. The remainder of each supernatant was rocked with
agarose beads conjugated to anti-FLAG antibody (Sigma) for two
hours to overnight at 4 1C. Finally, beads were washed four times
in cold immunoprecipitation buffer and stored at 201.
Protein samples were diluted in NuPAGE LDS sample buffer
(Life Technologies) containing DTT (ﬁnal concentration 50 mM),
incubated at 80 1C for ten minutes, and electrophoresed on a
precast acrylamide gel (Life Technologies) at 200 V. Proteins were
immobilized on PVDF paper by wet transfer at 33 V for 1–1.5 h.
PVDF papers were blocked in PBS with 0.1% tween-20 (PBT)
containing 5% milk and blotted with the following antibodies in
blocking solution for 1 h at room temperature: FLAG M2-
peroxidase 1:1000 (Sigma), HA-peroxidase 1:1000 (Roche), Heg
antibody 1:500 (see next paragraph). Blots probed with anti-Heg
antibody were washed three times and then incubated for
one hour with peroxidase-conjugated anti-rabbit antibody
(GE Healthcare) in blocking solution at 1:2500. After antibody
incubation, blots were washed three times in PBT before devel-
oping with SuperSignal West Pico Substrate or SuperSignal West
Dura Chemiluminescent Substrates (Thermo Scientiﬁc) as per the
manufacturer’s instructions.
A polyclonal antibody to the C-terminal region of Heg was
generated by immunizing rabbits with a synthetic peptide
designed from conceptual translation of the open reading frame.
For the Heg C-terminal epitope antibody HM2148, the peptide
PSFLSDDSRRRDYF was synthesized, then conjugated at the
N-terminus to KLH (Keyhole Limpet Hemocyanin) through a Cys-
6-carbon spacer (Princeton Biomolecules). Rabbits were injected
with the peptide immunogen using a typical schedule (initial sub-
cutaneous injection of 500 mg followed by 5 additional boosts with
250 mg at 21 day intervals; Covance Research). The terminal
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protocol and this serum was then afﬁnity puriﬁed.Results
ccm2l is a novel, conserved gene expressed during embryonic
development
To identify potential homologs of genes in the Heg-CCM
pathway, we queried the NCBI databases for entries with
sequence identity to Heg-CCM genes using both BLASTp and
BLASTx algorithms. We identiﬁed a protein bearing 43% identity
to Ccm2, which we have named Ccm2-like (Ccm2l) (Fig. 1A). The
coding sequence of ccm2l contains 1842 nucleotides and the
corresponding protein has 613 amino acids. The only domain in
Ccm2l readily predicted by the protein’s primary sequence is a
Pleckstrin-homology (PH) domain-like region comprised of amino
acids 45–146 (Gough et al., 2001). The PH-like domain super-
family includes PTB domains; since the PH-like domain in Ccm2l
has high identity to the PTB domain of Ccm2, we will refer to theFig. 1. Sequence and expression analysis of ccm2l. (A) Alignment of Ccm2l and Ccm2
Ccm2. The N-terminal region of Ccm2l contains a putative PTB domain with high identit
their C-termini. (C) RT-PCR showing expression of ccm2, ccm2l, ccm1 and the positive c
points tested between 0 and 48 hpf. Water (w) is included as a negative control. (D) RT
embryonic hearts (h) at 48 hpf. Both genes are expressed in the heart, with the ratio of h
heart-speciﬁc marker cardiac myosin light chain (cmlc2) and for a transcript absent fro
(E) In situ hybridization analysis of ccm2l expression. In 30 hpf embryos, ccm2l express
(arrowheads) and the tissue ventral to it (arrows). Embryos treated with sense prob
superfamily; PTB, phosphotyrosine binding domain; w, water.PH-like domain as a putative PTB domain. Ccm2l and Ccm2
contain regions of high identity not only in their PTB domains,
but also in their C-terminal ends (Fig. 1A,B). We ampliﬁed ccm2l
from RNA isolated from 2-day old embryos using primers corre-
sponding to the 5’ and 3’ ends of the coding region of the
transcript. Sequencing of our clone revealed that it matches the
full-length transcript predicted by the Ensembl Genome Browser.
ccm2l homologs are found in other vertebrate species, including
human, where it is called C20ORF160.
We performed RT-PCR and in situ hybridization to analyze
when and where in the embryo ccm2l is expressed. By RT-PCR we
found that transcripts for ccm2l, like ccm1 and ccm2, are present
at all time points we tested between fertilization and 48 h post
fertilization (hpf) (Fig. 1C). The presence of transcripts at the
zygote stage implies a maternal contribution of these messages.
Because the Heg-CCM pathway functions in heart development,
we mechanically puriﬁed 52 hpf zebraﬁsh embryonic hearts and
performed RT-PCR for ccm1 and ccm2l expression, and we found
that both genes are expressed in the heart (Fig. 1D). Next we
performed in situ hybridization for ccm2l. We found that at 30 hpf,
ccm2l is detectable in the presumptive notochord at the posteriorprotein sequences. (B) Schematic comparing the domain structures of Ccm2l and
y to the PTB domain of Ccm2. The two proteins also have regions of high identity at
ontrol gapdh at ﬁve embryonic stages. All four genes are expressed at all ﬁve time
-PCR comparing expression of ccm2l and ccm1 in whole embryos (e) and puriﬁed
eart expression to whole embryo expression much higher for ccm2l. RT-PCR for the
m the heart, insulin (ins), demonstrate the quality of the heart tissue puriﬁcation.
ion is detected in the posterior end of the embryo in the presumptive notochord
e as a negative control lack staining in these domains. PH, Pleckstrin-homology
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negative control sense probe does not produce any signal in these
domains (Fig. 1E). This expression pattern shares features with
those of ccm1 and ccm2; we have previously shown that ccm1 is
expressed in the notochord at 48 hpf and ccm2 is expressed in the
intermediate cell mass ventral to the notochord at 28 hpf (Mably
et al., 2006). The mouse homolog of ccm2l has previously been
shown to be enriched in embryonic-stem cell derived CD31þ
endothelial-like cells (Mariappan et al., 2009).
ccm2l is required for heart development
To characterize the role of ccm2l in zebraﬁsh development, we
employed a morpholino loss-of-function strategy. First, we
designed a morpholino, MO e4i4, to bind an exon–intron junction
in the ccm2l pre-mRNA. Microinjection of embryos with this
morpholino caused a heart phenotype with little overall toxicity,
but surprisingly, we could not detect any changes to the ccm2l
transcript when we performed RT-PCR using primers targeted to
neighboring exons. Others have reported the same phenomenon
and suggested that splice site morpholinos may in some cases
prevent efﬁcient translation (Schottenfeld et al., 2007). We
designed a second splice site morpholino, MO e2i2, and found
that it confers a similar phenotype to MO e4i4. RT-PCR followed
by sequencing demonstrated that MO e2i2 increases the amount
of an endogenous alternative transcript at the expense of the
expected transcript (Fig. 2A). Sequencing revealed that the alter-
native transcript contains an intronic inclusion with a premature
stop codon (Fig. 2B); thus, MO e2i2 appears to cause a shift from
normal Ccm2l protein to a severely truncated isoform. Splicing ofFig. 2. ccm2l morphants exhibit heart and inﬂow tract defects. (A) Injection of MO e2i2
expense of the presumptive functional transcript (arrowhead). (B) Sequencing reveals t
embryos injected with MO e2i2, incorporates intron 2, leading to an in-frame stop codo
tracts. (D,E,G,H) Embryos injected at the one-cell stage with 0.3 pMol MO e2i2 (D and
Embryos injected with MO e2i2 often have a curved body axis. All images are taken frccm2 at the homologous exon–intron junction is not affected
(Supplemental Fig. 1).
Loss-of-function of ccm2 in zebraﬁsh causes a massively
dilated heart phenotype (Mably et al., 2006). We began our
phenotypic study of ccm2l by asking whether its knockdown
affects heart development. At 52 hpf, uninjected embryos display
compact heart chambers, a narrow inﬂow tract, and robust
circulation (Fig. 2C,F). In contrast, we observe dilation of the
atrium in 25–50% of the embryos injected with MO e2i2
(Fig. 2D,G). This heart phenotype is coincident with dilation of
the inﬂow tract and in some embryos a complete cessation of
blood circulation despite a rhythmic heart beat. At 3 dpf, we still
observe dilation of the atrium (data not shown). Experiments
with MO e2i2 require a relatively low dose of morpholino, as
higher doses cause global developmental defects. Even at low
doses, typically some embryos had to be excluded from analysis
due to global defects. Embryos injected with MO e4i4 exhibit a
phenotype similar to those injected with MO e2i2, consisting of
dilated inﬂow tracts often accompanied by dilated atria at 2 dpf
(Fig. 2E,H), at a lower penetrance of 18%. Heart phenotypes
caused by either ccm2l morpholino are less severe than those
observed in ccm1, ccm2, and heg mutants; it is unknown whether
this distinction is biologically relevant or simply due to incom-
plete ccm2l knockdown.
Because our RT-PCR data show that MO e2i2 can cause heart
phenotypes even though a substantial amount of normal tran-
script remains in the embryo, we considered the possibility that
the inclusion of intron 2 generates a dominant negative protein.
To test this hypothesis, we injected mRNA containing the open
reading frame of this transcript and found that a small number ofincreases production of an endogenous alternatively spliced product (arrow) at the
hat the alternatively spliced ccm2l mRNA, which is observed at increased levels in
n. (C and F) Uninjected embryos have compact heart chambers and narrow inﬂow
G) or 1.0 pMol MO e4i4 (E and H) exhibit dilation of the atrium and inﬂow tract.
om a lateral perspective with anterior to the left. a, atrium; i.t., inﬂow tract.
Fig. 3. Effects of ccm2l disruption on embryonic vasculature. (A and B) At 52 hpf, control embryos have an appropriately constricted endocardium, while ccm2l morphants
exhibit endocardial dilation. (Arrows show lumen diameter). (C and D) Morphology of the CCV at 52 hpf is generally normal in ccm2l morphants. (E and F) At 58 hpf, ISVs
are mostly insensitive to ccm2l loss-of-function, although some affected embryos have ISVs that are not fully dilated (arrowhead). (G and H) At 72 hpf, SIVs in affected
embryos are frequently mispatterned. (I–K) At 52 hpf, MsVs are approximately the same width in control embryos and affected embryos (arrowheads). A and B are 20
magniﬁcation; C–J are 10 magniﬁcation. A–F are taken from a lateral perspective with anterior to the left; G and H are dorsal images with anterior to the right. I and J are
taken from a dorsal perspective with the anterior end tilted upward. In K, error bars represent standard error. Cont, standard control morpholino.
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appeared to have morphologically normal hearts and blood
circulation (Supplemental Fig. 2 A–D). Thus, we favor the hypoth-
esis that MO e2i2 causes a phenotype by incompletely knocking
down levels of Ccm2l, not by generating a protein with dominant
negative activity. Similarly, we found that morpholino against
ccm2 can confer an intermediate heart phenotype when injected
at doses that allow for a substantial amount of normal transcript
to endure ((Supplemental Fig. 2 E–K).
Next, we examined the effects of morpholino-mediated ccm2l
knockdown on the embryonic vasculature using the (ﬂi1:EGFP)y1
transgenic line, in which all endothelial cells are labeled with EGFP
(Lawson and Weinstein, 2002). We compared the morphology of
several vessels in embryos injected with a standard control mor-
pholino (cont MO) and those injected with MO e4i4; we chose this
morpholino for analysis because its low toxicity prevents secondary
vascular phenotypes caused by global developmental defects. We
examined the endocardium, common cardinal vein (CCV), and
mesencephalic veins (MsVs) at 52 hpf, the intersegmental veins
(ISVs) at 58 hpf and the subintestinal veins (SIVs) at 72 hpf. For this
analysis, we selected embryos displaying heart and inﬂow tractdefects. As expected, the morphant endocardium appears dilated
compared to embryos injected with cont MO (Fig. 3A,B). The CCVs in
affected embryos are generally normal (Fig. 3C,D). (We have
observed some CCVs exhibiting developmental delay at 2 dpf that
appear normal by 3 dpf.) We observe relatively minor defects in the
ISVs and SIVs; the ISVs in affected embryos are normally patterned
but a small number of vessels fail to lumenize (Fig. 3E,F), and SIVs
frequently display an irregular growth pattern (Fig. 3G,H). These
defects may be explained by a reduction in blood circulation, as
silent heart (sih) mutants, which completely lack blood ﬂow owing to
a defect in cardiac contractility, exhibit more severe versions of
those phenotypes (Hogan et al., 2008; Mably and Childs, 2010). It
was recently reported that combined knockdown of ccm3a and
ccm3b, but not ccm1 or ccm2, causes extreme dilation of the MsVs in
zebraﬁsh, a phenotype of particular interest because of its similarity
to dilated brain vessels in patients with CCM disease (Yoruk et al.,
2012). We observed that MsVs in cont MO-injected embryos are
approximately the same width as those in MO e4i4-injected
embryos (Fig. 3I,K). Taken all together, these data suggest that ccm2l
function may be more crucial for development of the endocardium
than for the other major vessels we investigated.
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The heart phenotype conferred by ccm2l morpholino injection
is consistent with a role for ccm2l in the Heg-CCM pathway. To
directly test whether there is a genetic interaction between ccm2l
and the Heg-CCM pathway, we undertook a morpholino co-
injection approach that we have used previously to demonstrate
genetic interactions among ccm1, ccm2, and heg (Mably et al.,
2006). We determined subphenotypic doses of ccm2l and ccm1
morpholinos and injected them either together or individually
with control morpholino. At 52 hpf, we assayed embryos for the
dilated heart phenotype we observe in heg, ccm1, and ccm2
mutants. Embryos were scored under light microscopy as either
wildtype, intermediate, or severe. Wildtype embryos have heart
morphology and blood circulation comparable to uninjected
embryos; intermediate embryos have moderately dilated heartsFig. 4. ccm2l interacts genetically with the Heg-CCM pathway. (A–C) For enhancer e
morpholino and ccm2l morpholino in pairwise combinations and assayed at 52 hpf for
and inﬂow tract comparable to uninjected embryos and strong blood circulation. ‘‘Int
maintain some level of blood circulation. ‘‘Severe’’ embryos have extreme dilation of the
morpholino with no predicted cellular targets, MO e2i2 and MO e4i4 both increase the
morpholino. Images of embryos were taken at 10x magniﬁcation from a lateral persp
independent experiments. For each group, n498 embryos. (D,E) For rescue experimen
mRNA transcribed in vitro from either wildtype ccm2 cDNA (ccm2wt) or from cDNA corr
in a signiﬁcant proportion of embryos injected with MO e2i2, while ccm2m201 RNA did n
morphology in a signiﬁcant proportion of embryos injected with MO e4i4. Embryos ex
inﬂow tract/atrium.’’ Graphs represent data pooled from three independent experi
contingency table using Fisher’s exact test. n.s., not signiﬁcant.and inﬂow tracks and often sluggish circulation; and severe
embryos have hugely dilated hearts and inﬂow tracts and com-
pletely lack circulation of red blood cells (Fig. 4A). Due to the
somewhat subjective nature of this rubric and the extreme
sensitivity of the experiment’s outcome to the precise injection
volume each embryo receives, the morpholino solutions were
blinded to the experimenter prior to injection and revealed after
all embryos were scored.
We found that both ccm2l morpholinos enhance the dilated
heart phenotype in embryos sensitized with ccm1 morpholino.
In experiments with MO e2i2, 49% of embryos receiving ccm1 and
ccm2l morpholinos had either intermediate or severe phenotypes,
while only 15% of embryos that received ccm1 morpholino
with the equivalent amount of control morpholino had
those phenotypes. Just 2% of embryos receiving MO e2i2 with
control morpholino had a heart phenotype (Fig. 4B). Inxperiments, embryos were injected with low doses of control morpholino, ccm1
heart morphology and function. (A) Embryos classiﬁed as ‘‘wildtype’’ have a heart
ermediate’’ embryos exhibit moderate dilation of the atrium and inﬂow tract but
heart and inﬂow tract and lack blood circulation. (B and C) Compared to a control
proportion of moderate and severe phenotypes in embryos sensitized with ccm1
ective with anterior to the left. Graphs represent data pooled from at least three
ts, embryos were injected with ccm2l morpholino and subsequently injected with
esponding to the ccm2 mutant allele ccm2m201. (D) ccm2wt RNA rescued circulation
ot. (E) Similarly, ccm2wt RNA but not ccm2m201 RNA rescued heart and inﬂow tract
hibiting an enlarged inﬂow tract and/or enlarged atrium were labeled as ‘‘dilated
ments. For each group, n4130 embryos. p-values are calculated from a 22
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and ccm2l morpholinos had either intermediate or severe pheno-
types, while only 4% of embryos that received ccm1 morpholino
with the equivalent amount of control morpholino had those
phenotypes. No embryos injected with MO e4i4 and control
morpholino developed abnormal heart phenotypes (Fig. 4C). We
conclude that ccm2l is an enhancer of the Heg-CCM heart
phenotype.
ccm2 overexpression partially rescues ccm2l morphant phenotypes
Due to the high degree of homology between Ccm2 and Ccm2l,
our observation that their knockdown confers similar phenotypes,
and our ﬁnding that ccm2l knockdown can enhance the heart
phenotype in ccm1 morpholino-sensitized embryos, we hypothe-
sized that ccm2 and ccm2l have overlapping in vivo functions. To
test this hypothesis, we attempted to rescue ccm2l morpholino-
injected embryos with synthetic ccm2mRNA. Since the severity of
phenotype caused by our ccm2l morpholinos is sensitive to the
volume of morpholino received by the embryo, we used a double-
injection approach to insure that all groups, on average, received
the same amount of ccm2l morpholino. First we injected a large
pool of embryos with ccm2l morpholino and then randomly
divided the pool into three groups. One group was re-injected
with wildtype ccm2mRNA, the second group was re-injected with
ccm2 mRNA transcribed from a loss-of-function allele isolated
from the zebraﬁsh mutant ccm2m201 as a negative control, and the
third group did not receive a second injection. At 52 hpf, embryos
were assayed in a blind fashion.Fig. 5. Biochemical interactions among proteins of the Heg-CCM pathway. (A) Schemat
ccm1 and FLAG-ccm1DFERM co-immunoprecipitate HA-ccm2 and HA-ccm2l, while t
contrast, FLAG-ccm1DFERM does not co-immunoprecipitate Heg, while the N-termi
weakened by mutation of Ccm1’s two NPXY motifs and further disrupted by mutat
FLAG-ccm1 is unaffected by mutation of Ccm1’s NPXY motifs but is severely dimini
unaffected by mutation of either two or all three NPXY/F motifs in Ccm1. (D) The mutan
as well as wildtype FLAG-ccm1 does, but they do not bind Heg.In experiments with MO e2i2, we used circulation down the
trunk of the embryo as a functional readout for cardiovascular
rescue. Embryos injected with only MO e2i2 or MO e2i2 and
ccm2m201 mRNA had blood circulation at rates of 53% and 52%,
respectively. In contrast, embryos that received MO e2i2 and
ccm2wt mRNA had circulation at a frequency of 73% (Fig. 4D). We
observed the same trend with MO e4i4. In rescue experiments
with this morpholino, we scored embryos by heart and inﬂow
tract morphology rather than blood circulation because MO e4i4
exhibits low penetrance and rarely causes circulatory block. We
found that 82% and 85% of embryos injected with only MO e4i4 or
MO e4i4 and ccm2m201 mRNA, respectively, had normal hearts and
inﬂow tracts. However, 91% of embryos that received MO e4i4
and ccm2wt mRNA had normal hearts and inﬂow tracts (Fig. 4E).
For both morpholinos, rescue achieved by ccm2wt mRNA was
statistically signiﬁcant, whereas any rescue achieved by ccm2m201
mRNA was not.
Ccm2l binds Ccm1
Next, we sought a molecular explanation for our phenotypic
results linking ccm2l to the Heg-CCM pathway. Based on its
homology to Ccm2, which is known to bind Ccm1 (Zawistowski
et al., 2005; Zhang et al., 2007), we hypothesized that Ccm2l binds
Ccm1 as well. To test this hypothesis, we overexpressed epitope-
tagged versions of Ccm1 and Ccm2l in 293T cells, and then
immunoprecipitated Ccm1 and blotted for Ccm2l. As a positive
control, we performed the same experiment with Ccm1 and
Ccm2. We found that both HA-ccm2 and HA-ccm2l bindic of all Ccm1 constructs used for co-immunoprecipitation experiments. (B) FLAG-
he N-terminal Ccm1 deletion proteins do not bind HA-ccm2 and HA-ccm2l. In
nal Ccm1 deletion proteins do. (C) HA-ccm2 binding to FLAG-ccm1 is severely
ions in the NPXF motif. The strength of the interaction between HA-ccm2l and
shed when all three NPXY/F motifs are mutated. Heg-Ccm1 interactions appear
t Ccm1 proteins FLAG-ccm1ty219c and FLAG-ccm1m775 bind HA-ccm2 and HA-ccm2l
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ccm2l are both expressed in the heart (Fig. 1D), this interaction in
cell culture likely recapitulates an endogenous interaction.
To further deﬁne the interaction between Ccm2l and Ccm1, we
performed a deletion analysis to determine which domains of
Ccm1 bind Ccm2l. We generated two N-terminal Ccm1 deletion
constructs, one lacking the three NPXY/F motifs and the other
lacking these motifs as well as the ankyrin repeats, and a
C-terminal deletion construct lacking the FERM domain. All these
constructs contain an N-terminal FLAG tag (Fig. 5A). In the 293T
cell overexpression system, we found that protein generated from
the C-terminal deletion construct, FLAG ccm1DFERM, efﬁciently
bound HA-ccm2l. In contrast, FLAG-ccm1DNPXY/F and FLAG-
ccm1DNPXY/F-ANK did not bind HA-ccm2l (Fig. 5B). We observed
the same result for Ccm1 binding to Ccm2 (Fig. 5B), consistent
with others’ work demonstrating an interaction between the
N-terminal domain of human CCM1 and CCM2 (Zhang et al., 2007).
We also performed the same deletion analysis to determine
which domains of Ccm1 are necessary to bind Heg, using a
polyclonal antibody against Heg. We found that Ccm1 proteins
with N-terminal deletions efﬁciently co-immunoprecipitate Heg.
In contrast, Ccm1 protein lacking the FERM domain does not
(Fig. 5B). We saw the same result when we replaced full-length
Heg with Heg protein lacking its entire extracellular domain
(Supplemental Fig. 3). Thus, the C-terminal FERM domain-
containing region of Ccm1 is necessary and sufﬁcient to bind
the intracellular domain of Heg. These results are in contrast
to Ccm1’s interactions with Ccm2 and Ccm2l, for which the
C-terminal region of Ccm1 is dispensable but the N-terminal
region is essential. Consistent with our studies of the zebraﬁsh
proteins, it was recently shown that human HEG1 interacts with
the FERM domain of CCM1 (Gingras et al., 2012).
The N-terminal region of zebraﬁsh Ccm1 contains two NPXY
motifs and one NPXF motif. Since Ccm2l contains a putative PTB
domain, we hypothesized that the Ccm2l–Ccm1 interaction
requires these motifs. To test this hypothesis, we generated two
mutant ccm1 constructs (Fig. 5A). In the ﬁrst, FLAG-ccm1-AA, we
altered both NPXY motifs by mutating the tyrosine residue in
each to alanine. The second, FLAG-ccm1-AAAA, contains those
mutations as well as two mutations in the NPXF motif. We doubly
mutated the NPXF motif because the residue occupying the third
position (‘‘X’’) is a tyrosine. Since either the tyrosine or the
phenylalanine could be mediating a protein binding interaction,
we converted both to alanine. We found that FLAG-ccm1-AA
binds HA-ccm2l as strongly as wildtype FLAG-ccm1, but binding
of FLAG-ccm1-AAAA to HA-ccm2l is extremely diminished. In
contrast, we found that the interaction between FLAG-ccm1-AA
and HA-ccm2 is diminished relative to the interaction between
wildtype FLAG-ccm1 and HA-ccm2, and that the interaction
between FLAG-ccm1-AAAA and HA-ccm2 is weaker still (Fig. 5C).
Thus, the NPXY motifs of Ccm1 are required for strong binding of
Ccm1 to Ccm2 but dispensable for binding of Ccm1 to Ccm2l. As a
control, we also tested the interactions between Ccm1 NPXY/F
mutant proteins and Heg. Consistent with our ﬁnding that the N-
terminal region of Ccm1 is not required for binding to Heg, FLAG-
ccm1-AA and FLAG-ccm1-AAAA bind Heg as strongly as wildtype
FLAG-Ccm1 (Fig. 5C).
Finally, we sought to determine whether the defective Ccm1
proteins produced by our ccm1 mutant ﬁsh are capable of binding
Ccm2l, Ccm2, and Heg. The mutant alleles ccm1ty219c and
ccm1m775 have a point mutation and deletion, respectively, within
the 30 end of the mRNA that are predicted to disrupt the FERM
domain in both cases (Mably et al., 2006) (Fig. 5A). We subcloned
these mutant alleles into expression plasmids with FLAG tags and
found that both produce proteins that can bind Ccm2 and Ccm2l.
However, neither mutant Ccm1 protein can bind Heg (Fig. 5D).The FERM domain of Ccm1 has been shown to bind the small
GTPase RAP1 and membrane proteins such as b-CATENIN
(Glading et al., 2007; Liu et al., 2011). We hypothesize that the
ccm1m775 and ccm1ty219c mutant embryos exhibit their heart
phenotype owing to an inability of Ccm1 to bind these proteins
as well as Heg, rather than an inability to bind Ccm2 and Ccm2l.Discussion
ccm2l is required for normal cardiovascular development
We identiﬁed Ccm2l as a novel, conserved protein bearing
considerable identity to Ccm2, and performed a loss-of-function
analysis using two nonoverlapping morpholinos targeted to
exon–intron junctions in the ccm2l pre-mRNA. ccm2l morphants
exhibit dilation of the atrium and inﬂow tract and in severely
affected embryos reduced or absent blood circulation. The heart
and inﬂow tract phenotypes we observe in ccm2l morphants are
reminiscent of but less severe than the phenotypes in ccm1, ccm2,
and heg mutants. ccm2l morphants may have a more mild heart
phenotype than these mutants because ccm2l has a more subtle
role in heart development, or the difference could simply be a
reﬂection of incomplete ccm2l knockdown. In the future, genera-
tion of a ccm2l null mutant will be crucial to resolving this
ambiguity.
Morpholino disruption of ccm2l also confers subtle defects in
other regions of the vasculature; in ccm2l morphants, a small
number of ISVs fail to lumenize, and many SIVs have unusual
growth patterns. The ISV and SIV phenotypes may be due to
compromised blood ﬂow in the embryo, since sih mutants, which
have no blood circulation, have more severe versions of these
phenotypes (Hogan et al., 2008; Mably and Childs, 2010). While
we favor the interpretation that the primary function of ccm2l is
to regulate heart morphology and the extra-cardiac vascular
defects in ccm2l morphants are due to reduced blood circulation
caused by heart dilation, we cannot yet rule out the possibility
that ccm2l functions directly in vessels outside the heart.
Our in situ hybridization data showing ccm2l expression in the
notochord and ICM do not correlate with our ﬁndings that ccm2l
is essential for heart development. While it is possible that ccm2l
could regulate heart morphogenesis from a distant location, we
believe the more likely explanation for the discrepancy between
expression pattern and phenotype is that our in situ hybridization
protocol is insufﬁciently sensitive to detect ccm2l in the heart. In
support of this reasoning, we can detect by RT-PCR ccm2l
transcript in hearts dissociated from 2 dpf embryos. The case
with ccm1 is similar; ccm1 is required for heart development and
is detectable in puriﬁed hearts by RT-PCR, yet we have been
unable to detect ccm1 expression in the embryonic heart by in situ
hybridization. Based on our phenotypic and RT-PCR data, as well
as the literature in the ﬁeld, we think that the Heg-CCM pathway,
including ccm2l, has a tissue-autonomous function in the heart’s
endocardium. Tissue-speciﬁc manipulations of the Heg-CCM
pathway will be required to demonstrate this.
ccm2l is a component of the Heg-CCM pathway
We conclude that ccm2l is a component of the Heg-CCM
pathway based on four lines of evidence. First, disruption of ccm2l
by morpholino injection causes dilation of the atrium and inﬂow
tract. These phenotypes are less severe than those conferred by
knockdown of ccm1, ccm2, or heg, but qualitatively similar.
Second, mild knockdown of ccm2l enhances the dilated heart
phenotype in embryos treated with a subphenotypic dose of ccm1
morpholino. This morpholino co-injection technique was previously
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ﬁnding was subsequently validated by genetic and biochemical
experiments in mouse (Kleaveland et al., 2009). Third, ccm2l
knockdown phenotypes can be partially rescued by overexpres-
sion of ccm2, suggesting that the two genes have partially
overlapping in vivo functions. Fourth, Ccm2l protein can
bind Ccm1.
We propose a model in which Ccm2 and Ccm2l function
similarly in the Heg-CCM complex (Fig. 6). Both Ccm2 and Ccm2l
bind the N-terminal region of Ccm1 through Ccm1’s NPXY/F
motifs, and we speculate that there is overlap between the
downstream signaling events triggered by both interactions. In
our model, when ccm2l is knocked down, exogenously supplied
ccm2 can recover the downstream signaling events that are
common to the two complexes. Thus, overexpression of ccm2
can rescue ccm2l morphant defects in a signiﬁcant proportion of
embryos. Our rescue data are also consistent with models in
which ccm2 functions downstream of ccm2l, but we favor the
interpretation that they have interchangeable in vivo functions
because of their structural similarity and our ﬁnding that Ccm2l,
like Ccm2, binds Ccm1.
The molecular details of how Ccm2l interacts with other
proteins in the Heg-CCM pathway are unknown. For example, it
is unclear whether Ccm1 binds to Ccm2 and Ccm2l in a
mutually exclusive manner in vivo, or whether Ccm2 and Ccm2l
can simultaneously bind Ccm1. It is interesting to note here that
the ﬁrst two NPXY/F motifs in Ccm1 are jointly necessary for
binding to Ccm2 but dispensable for binding to Ccm2l, which
raises the possibility that Ccm2 and Ccm2l bind different NPXY/F
motifs in vivo and might be able to bind Ccm1 simultaneously.
Finer mutational analysis of the NPXY/F motifs in Ccm1 and
biochemical characterization of in vivo Heg-CCM complexes will
be required to resolve this question. Additionally, more analysis
will be required to determine whether the third NPXY/F motif inFig. 6. Model for the function of ccm2l in cardiovascular development. In our
model, Ccm2l binds Ccm1 through Ccm1’s N-terminal region. When the two NPXY
motifs in Ccm1 are disrupted, the NPYF motif is sufﬁcient to allow binding
between Ccm1 and Ccm2l. This differs from the Ccm2–Ccm1 interaction, for which
the NPXY motifs are required for full-strength binding. We hypothesize that
although the NPXY/F motif requirements for the Ccm1–Ccm2l and Ccm1–Ccm2
interactions differ, the two complexes transduce partially overlapping signals.
Thus, when Ccm2l is reduced, exogenously supplied Ccm2 can rescue heart
morphology and blood circulation in a substantial proportion of embryos. The
downstream signaling events common to the Ccm1–Ccm2 and Ccm1–Ccm2l
interactions are essential for normal cardiovascular development, and in their
absence the endocardium and inﬂow tract become dilated and blood circulation is
compromised.Ccm1 is the site of Ccm2l binding, or whether due to redundancy,
any NPXY/F motif by itself would be sufﬁcient for binding
to Ccm2l.
The third NPXY/F motif, the only one of the three motifs with a
phenylalanine (F) instead of a tyrosine (Y) in the fourth position,
is also interesting for another reason. In general, NPXY and NPXF
motifs bind similar targets but only NPXY motifs can be
regulated by tyrosine phosphorylation. However, in Ccm1, the
third position in the NPXF motif is occupied by a conserved
tyrosine, and a recent mass spectrometry study found that this
residue was the only detectable phosphotyrosine in human CCM1
(Kim et al., 2011). In future studies it will be valuable to
determine whether phosphorylation at this site regulates binding
of Ccm1 to Ccm2 and/or Ccm2l.
ccm2l in zebraﬁsh and in mouse
While this paper was under review, our colleagues published a
study of the function of the mouse ortholog of ccm2l (Zheng et al.,
2012). Some of the ﬁndings of Zheng et al. on the role of Ccm2L in
mouse are consistent with our ﬁndings on the role of ccm2l in
zebraﬁsh, and some are different. Zheng et al. generate a Ccm2L
knockout mouse and ﬁnd that it is viable with no gross
cardiovascular defects, unlike ccm2l morpholino-injected zebra-
ﬁsh embryos that exhibit cardiac dilation. However, in a Ccm2L-/-
background, the Heg1-/- phenotype is enhanced; Heg1-/-
;Ccm2Lþ/- mice survive to birth, while Heg1-/-;Ccm2L-/- animals
die in utero from cardiac defects. This elegant genetic experiment
is analogous to our morpholino co-injection experiments, in
which we ﬁnd that slight knockdown of ccm2l can enhance the
cardiac defects in embryos sensitized with a low dose of ccm1
morpholino. Thus, in both zebraﬁsh and mouse, knockdown of
Ccm2L enhances heart defects in embryos that already have a hit
to the Heg-CCM pathway. Interestingly, in mouse, this
enhancement can be suppressed by loss of one allele of Ccm2.
That is, Heg1-/-;Ccm2L-/-;Ccm2þ/þ mice invariably die in utero,
but a signiﬁcant proportion of Heg1-/-;Ccm2L-/-;Ccm2þ/- mice
survive until birth. These genetic data arguing for antagonistic
functions for Ccm2 and Ccm2L contrast with our zebraﬁsh data
showing rescue of ccm2l knockdown phenotypes by ;overexpres-
sion of ccm2.
We hypothesize that the difference in the relationships between
ccm2 and ccm2l in zebraﬁsh and mouse is due to the disparate
mechanisms of heart growth that operate in the two species. Zheng
et al. show that Heg1-/-;Ccm2L-/- hearts have a reduction in both
trabeculation and expression of growth factors known to be
secreted by the endocardium to promote myocardial proliferation.
As a result, embryos die from inadequate heart growth, a
phenotype that can be rescued by loss of one Ccm2 allele. In
zebraﬁsh, however, neither trabeculation nor myocardial
proliferation are prominent features of development during the
stages of embryogenesis we examine. Trabeculation in the zebraﬁsh
ventricle does not begin until 72 hpf (Liu et al., 2010), a time point
outside of the scope of our experiments. Although the number of
cardiomyocytes increases between 24 and 48 hpf, proliferating
cardiomyocytes are scarce; instead, the main mechanism of heart
growth is the addition of newly differentiated cardiomyocytes
(de Pater et al., 2009). Given the absence of trabeculation and
signiﬁcant myocardial proliferation, we believe the control of heart
development by competitive interactions between Ccm2 and
Ccm2L observed by Zheng et al. in mouse would likely not be
conserved in the early zebraﬁsh embryo. It is also possible that some
of the apparently species-speciﬁc differences are due to different
methods of gene knockdown. In the future, it will be extremely
valuable to analyze the function of ccm2l using a zebraﬁsh null
mutant.
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In humans, loss-of-function mutations in CCM1 and CCM2 cause
vascular malformations of the nervous system called CCMs. CCMs
share certain features with ccm1 and ccm2mutant zebraﬁsh hearts. In
both cases, vessels become severely dilated and electron microscopy
reveals defects in the formation of tight junctions between endothe-
lial cells (Kleaveland et al., 2009; Wong et al., 2000). Owing to the
genetic and cell biological similarities between the dilated heart
phenotype in zebraﬁsh embryos and human CCMs, we propose that
the zebraﬁsh heart has promise as a model to understand CCM
disease. In one human genetics study, only 94% and 57% of patients
with familial and sporadic CCM disease, respectively, had mutations
in the coding regions of the three known CCM-associated genes
(Denier et al., 2006). Thus, there are likely more malformation-
causing genes to be found. Moreover, CCMs range from asymptomatic
to fatal, so even in patients with known disease-causing mutations
there may be other genetic modiﬁers that inﬂuence disease severity.
It stands to reason that genes that modify the ccm1 and ccm2 loss-of-
function heart phenotypes in zebraﬁsh may also inﬂuence CCM
pathogenesis in humans. In our studies, we identify ccm2l as an
enhancer of the dilated heart phenotype in the zebraﬁsh embryo. We
propose that the human homolog of ccm2l, C20ORF160, is an intri-
guing candidate gene to be investigated for mutations in patients
with CCM disease of unknown genetic etiology or in patients with
characterized mutations but unusually severe disease progression.Conclusions
We conclude that ccm2l is essential for cardiovascular develop-
ment in zebraﬁsh due to its function in the Heg-CCM pathway. When
ccm2l is knocked down, the embryonic atrium and inﬂow tract
become dilated and blood ﬂow is compromised. Slight perturbation
of ccm2l enhances the dilated heart phenotype in embryos sensitized
by morpholino against ccm1, deﬁning ccm2l as an enhancer of the
Heg-CCM pathway. Overexpression of ccm2 partially rescues ccm2l
morphant defects, which suggests that ccm2 and ccm2l have over-
lapping in vivo functions. ccm2l and ccm1 are both expressed in the
heart, and Ccm2l protein binds Ccm1 in an interaction that requires
Ccm1’s NPXY/F motifs; however, unlike Ccm2, Ccm2l can bind Ccm1
even when the ﬁrst two of the three NPXY/F motifs are mutated.
Based on the role of ccm2l in the Heg-CCM pathway in zebraﬁsh, the
human ortholog of ccm2l, C20ORF160, may be relevant to human CCM
disease.
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